Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0178874 (
tumor progression
)
40,807
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Elevated levels of
pp60c-src
tyrosine kinase activity have been implicated in both tumorigenesis and cell differentiation. We have found a 2- to 4-fold elevation in
pp60c-src
specific activity in certain human melanoma cell lines compared to human foreskin fibroblasts. This activation of
pp60c-src
did not appear to be related to melanoma
tumor progression
, because when normal human epidermal melanocytes were examined, it was found that they contained
pp60c-src
having a 7-fold elevation in specific activity compared to
pp60c-src
from human fibroblasts. It was determined that
pp60c-src
from melanocytes was not the neuronal form, pp60c-src+. Melanocyte
pp60c-src
exhibited a reduced level of phosphorylation on its carboxyl-terminal regulatory site, tyrosine 530, which might be responsible for its elevated specific activity. These results suggest that, in melanocytes, regulation of tyrosine 530 phosphorylation-dephosphorylation favors activation of
pp60c-src
. This activation may be involved in the growth, differentiation, or function of human melanocytes.
...
PMID:pp60c-src in human melanocytes and melanoma cells exhibits elevated specific activity and reduced tyrosine 530 phosphorylation compared to human fibroblast pp60c-src. 138 53
Colonic neoplasia provides an opportunity to study
tumor progression
because most carcinomas arise from adenomas (polyps), which, in turn, arise from normal epithelia. The malignant potential of adenomas varies with size, histology, and degree of dysplasia. Polyps that are less than 2 cm with villous architecture and severe dysplasia are most likely to contain carcinoma. Previous studies demonstrated that the in vitro protein-tyrosine kinase activity of
pp60c-src
from colon carcinomas is significantly higher than that from adjacent normal mucosa. Here we report that the protein kinase activity of
pp60c-src
is also elevated in colonic polyps. Activity is highest in malignant polyps and in greater than 2-cm benign polyps that contain villous structure and severe dysplasia. Thus,
pp60c-src
activation occurs in benign polyps that are at greatest risk for developing cancer. These data suggest that activation of the protooncogene product
pp60c-src
may be an important event in the genesis of human colon carcinoma.
...
PMID:Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. 210 87
Tumor-derived Syrian hamster embryo (SHE) cell lines, induced in vitro by treatment with chemical carcinogens, contained increased levels of
pp60c-src
kinase activity compared to preneoplastic parental cell lines and normal SHE cells. The increased kinase activity did not result from an increase in the
pp60c-src
content of the SHE cell lines, but represented a 4-11 fold increase in
pp60c-src
kinase specific activity. Both the extent of phosphorylation and the velocity of
pp60c-src
phosphotransferase activity were increased in the tumor-derived cell lines. SHE cell lines producing chicken
pp60c-src
were isolated following co-transfection with plasmids bearing the chicken c-src and neoR genes. Chicken
pp60c-src
expressed in an asbestos-transformed, tumor-derived cell line showed an approximate 3-fold activation of tyrosine kinase activity compared to chicken
pp60c-src
expressed in the preneoplastic cell line. We suggest that these results indicate that activation of
pp60c-src
is mediated by trans-acting cellular factors present in the tumor-derived cells. Analysis of
pp60c-src
in normal SHE cells, preneoplastic cell lines and tumor-derived cell lines showed no alteration in the phosphorylation of tyr-527 or tyr-416, two tyrosine residues whose phosphorylation states have been associated with modulation of kinase activity. These studies indicate that the
neoplastic progression
of cells may be accompanied by the activation of proto-oncogene products, such as the
pp60c-src
tyrosine kinase, by mechanisms that may not directly involve genetic alteration of the proto-oncogene DNA sequence.
...
PMID:Activation of pp60c-src tyrosine kinase specific activity in tumor-derived Syrian hamster embryo cells. 245 99
Transgenic mice expressing the polyomavirus (PyV) middle T oncogene in the mammary epithelium develop multifocal mammary tumors that metastasize with high frequency. The potent transforming activity of PyV middle T antigen can, in part, be attributed to its ability to associate with and to activate a number of
c-Src
family tyrosine kinases (
c-Src
, c-Yes, and Fyn). As a first step toward assessing the role of individual
c-Src
family tyrosine kinases in PyV middle T antigen-induced mammary tumorigenesis, we have crossed transgenic mice carrying the mouse mammary tumor virus (MMTV)/PyV middle T antigen fusion gene with mice bearing a disrupted c-src proto-oncogene. In contrast to the rapid
tumor progression
seen in the original MMTV/PyV middle T antigen strains, mice expressing the transgene in the absence of functional
c-Src
rarely developed mammary tumors. After long latency, these mice did eventually develop abnormal hyperplastic mammary tissue. This growth disturbance was correlated with elevated expression of the PyV middle T antigen and the activation of the PyV middle T antigen-associated c-Yes tyrosine kinase. However, transgenic mice expressing the PyV middle T antigen in the mammary epithelium of wild-type or Yes-deficient mice developed multifocal mammary tumors with comparable kinetics. Taken together, these findings suggest that
c-Src
tyrosine kinase activity is required for PyV middle T antigen-induced mammary tumorigenesis and also illustrate an in vivo genetic approach to the dissection of mitogenic signal transduction pathways.
...
PMID:Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. 750 74
The molecular events regulating the development and progression of colonic neoplasia are currently being delineated. Recent studies have implicated
c-Src
protein kinase activation as an early event in the malignant transformation of colonic epithelial cells. However, increased
c-Src
activity has also been reported in colon carcinomas as well as in metastatic hepatic and extrahepatic colon carcinomas. To further investigate the potential role of
c-Src
in the progression of colonic neoplasia, we analyzed
c-Src
levels by immunohistochemistry in 27 colorectal resection specimens. Mouse monoclonal antibody to
c-Src
protein was applied to 3-micron sections from formalin-fixed, paraffin-embedded tissues using the avidin-biotin-peroxidase method. The combination of adenomatous (AD) and adjacent carcinomatous mucosa (CA) specimens were present in 20 of 27 patients. In 15 cases, synchronous metastatic (MT) lesions were available for evaluation. Strong
c-Src
expression was evident in 95% of AD (n = 20), in contradistinction to 32% of MT (n = 19) and 14% of CA (n = 22). Weak-to-moderate
c-Src
expression was seen in adjacent normal colonic mucosa (NM) in 96% of cases. Signed rank test univariate analysis revealed a statistically significant difference in
c-Src
expression between NM/AD (p = 0.0001), NM/CA (p = 0.0001), NM/MT (p = 0.0006), AD/CA (p = 0.0001), and AD/MT (p = 0.0002). No significant correlation between levels of
c-Src
expression and patient survival, tumor size, histologic grade, or tumor configuration was observed using the Cox's Regression Model. Similar results were obtained by analysis of
c-Src
protein levels and
c-Src
kinase activity as measured by Western blot and in vitro kinase assays of representative cases. Our results indicate that: (a) elevated
c-Src
expression is an important early event during colorectal carcinogenesis; (b) its activation may be involved in
tumor progression
in a subset of colonic carcinomas; and (c) additional molecular events are necessary for invasion to occur.
...
PMID:Elevated c-Src protein expression is an early event in colonic neoplasia. 952 Sep 49
In C3H/10T1/2 murine fibroblasts, overexpression of both
c-Src
and the human epidermal growth factor (EGF) receptor 1 (HER1) is required for detection of stable complexes between the two molecules and results in hyperactivation of the receptor and synergistic increases in tumor formation in nude mice, as compared with cells that overexpress only one of the pair. Elevated levels or activities of
c-Src
and HER1 also occur in a subset of later-stage breast cancers, suggesting that interactions between these two molecules could contribute to a more aggressive clinical course. To determine whether stable complexes between
c-Src
and HER1 occur in human breast cancers under the same conditions as in murine fibroblasts and whether the appearance of such complexes correlates with enhanced signaling through the EGF receptor and increased tumor growth, human breast tumor cell lines and tumor tissues were analyzed for a number of
c-Src
/HER1-mediated signaling events and tumorigenicity. In a panel of 14 cell lines, 10 overexpressed
c-Src
, and of these, five contained elevated levels of HER1 and exhibited an EGF-dependent association between HER1 and
c-Src
. This association was also present in a HER1/
c-Src
-overexpressing tumor sample from a breast cancer patient. Further analysis of signaling events revealed that phosphorylation of the HER1 substrate, Shc, and its downstream effector, mitogen-activated protein kinase, was increased in EGF-stimulated MDA-MB-468, MDA-MB-231, and BT-549 cells (which overexpress both
c-Src
and HER1) as compared with MCF7 and ZR-75-1 cells (which only overexpress
c-Src
). Furthermore, MDA-MB-468 and MDA-MB-231 cells displayed increased tumorigenicity in nude mice. These results support the hypothesis that
c-Src
/HER1 interactions contribute to
tumor progression
in certain late-stage breast tumor cells.
...
PMID:Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. 958 56
Calpain, also named CANP (for calcium-activated neutral protease), is an intracellular cytoplasmatic non-lysosomal cysteine endopeptidase that requires calcium ions for activity. Many substrates of the calpain isoenzymes, such as the transcription factors c-Fos and c-Jun, the tumor supressor protein p53, protein kinase C,
pp60c-src
and the adhesion molecule integrin, have been implicated in the pathogenesis of different human tumors, suggesting an important role of the calpains in malignant diseases. We now report differential expression of the calpain I gene (CL I) in a variety of tumors, extending our study to a larger series of renal cell carcinomas. Using Northern-blot analysis, we studied calpain I expression in 30 renal cell carcinomas as compared with matched healthy tissues. Tumor samples were classified according to their histological type: 21 clear cell carcinomas, 4 chromophobe carcinomas, 3 papillary carcinomas and 2 oncocytomas. In renal tumor samples, calpain I gene mRNA was expressed at highly variable levels, significantly depending on the different histological types. Moreover, there was a correlation of higher calpain I expression with increased malignancy: within the clear cell carcinoma subset, tumor samples with advanced nodal status (N1 and N2) showed a significantly higher calpain I expression than tumors without metastasis to regional lymph nodes. Our data suggest an important role of calpain isoenzymes in carcinogenesis and
tumor progression
.
...
PMID:Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type. 998 24
Accumulating evidence indicates that interactions between the epidermal growth factor receptor (EGFR) and the nonreceptor tyrosine kinase
c-Src
may contribute to an aggressive phenotype in multiple human tumors. Previous work from our laboratory demonstrated that murine fibroblasts which overexpress both these tyrosine kinases display synergistic increases in DNA synthesis, soft agar growth, and tumor formation in nude mice, and increased phosphorylation of the receptor substrates Shc and phospholipase gamma as compared with single overexpressors. These parameters correlated with the ability of
c-Src
and EGFR to form an EGF-dependent heterocomplex in vivo. Here we provide evidence that association between
c-Src
and EGFR can occur directly, as shown by receptor overlay experiments, and that it results in the appearance of two novel tyrosine phosphorylations on the receptor that are seen both in vitro and in vivo following EGF stimulation. Edman degradation analyses and co-migration of synthetic peptides with EGFR-derived tryptic phosphopeptides identify these sites as Tyr845 and Tyr1101. Tyr1101 lies within the carboxyl-terminal region of the EGFR among sites of receptor autophosphorylation, while Tyr845 resides in the catalytic domain, in a position analogous to Tyr416 of
c-Src
. Phosphorylation of Tyr416 and homologous residues in other tyrosine kinase receptors has been shown to be required for or to increase catalytic activity, suggesting that
c-Src
can influence EGFR activity by mediating phosphorylation of Tyr845. Indeed, EGF-induced phosphorylation of Tyr845 was increased in MDA468 human breast cancer cells engineered to overexpress
c-Src
as compared with parental MDA 468 cells. Furthermore, transient expression of a Y845F variant EGFR in murine fibroblasts resulted in an ablation of EGF-induced DNA synthesis to nonstimulated levels. Together, these data support the hypothesis that
c-Src
-mediated phosphorylation of EGFR Tyr845 is involved in regulation of receptor function, as well as in
tumor progression
.
...
PMID:c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. 1007 41
Various mechanisms of epithelial cell plasticity in morphogenesis have been studied at the genetic and molecular levels. Several control genes have been identified including genes encoding transcription factors and growth factor receptors. These mechanisms may be reactivated during the progression of carcinomas. One of the mechanisms underlying epithelial plasticity is the epithelial-mesenchymal transition. This process has been extensively studied using the NBT-II bladder carcinoma cell line. Cells of this line undergo a reversible transition following exposure to several growth factors including FGF-1, EGF, TGFalpha and SF/HGF, which activate tyrosine kinase surface receptors. Two separate transduction pathways have been identified. The transient activation of
c-Src
is involved in cytoskeleton remodeling whereas the Ras pathway controls the transcription of genes such as the transcription factor Slug which is involved in the internalization of desmosomes. These two pathways cooperate to induce the morphological transition, scattering and locomotion of fibroblast-like cells. Growth/scatter factor-producing NBT-II cells are more invasive than cells that do not contain this factor, in orthotopic confrontation assay. In vivo, these cells are very tumorigenic and may confer a more malignant phenotype on parental cells via a community effect. The role of several growth factors and their receptors has been investigated in human bladder carcinomas. A subset of these tumors with poor outcomes produce low levels of FGFR2-IIIb. The synthesis of this receptor de novo in bladder cell lines reduces proliferation in vitro and tumor growth in nude mice. FGFR2-IIIb functions as a tumor suppressor, consistent with the differentiation-inducing capacities of FGF receptors in the suprabasal cells of the skin. FGFR2-IIIb signaling may be involved in the maintenance of E-cadherin, the prototype epithelial adhesion molecule, which is only downregulated in a fraction of tumors with low FGFR2-IIIb synthesis. Human bladder tumors may also activate autocrine loops such as that for EGFR and their ligands, as already demonstrated for murine bladder tumors. Therefore, our results suggest that multifunctional growth factors and their receptors are involved in cell proliferation and epithelial cell plasticity, acting either as positive or negative regulators of
tumor progression
. The effect on the morphological transition is also clearly relevant to the mechanism governing dissemination and the formation of micrometastatic tumor cells. The extrapolation of these discoveries to human carcinomas should provide markers facilitating the more accurate prediction of the biological behavior of a given tumor and identify clinically and pathologically significant parameters. The identification of critical changes in the growth factor pathways involved in
tumor progression
will not only provide insight into the genetic and molecular basis of this process, but should also identify targets for new therapies.
...
PMID:Epithelial cell plasticity in development and tumor progression. 1050 44
Tissue factor (TF), apart from activating the extrinsic pathway of the blood coagulation, is a principal regulator of embryonic angiogenesis and oncogenic neoangiogenesis, but also influences inflammation, leukocyte diapedesis and
tumor progression
. The intracellular domain of TF lacks homology to other classes of receptors and hence the signaling mechanism is poorly understood. Here we demonstrate that factor VIIa (the natural ligand for TF) induces the activation of the Src family members
c-Src
, Lyn, and Yes, and subsequently phosphatidylinositol 3-kinase (PI3K), followed by stimulation of c-Akt/protein kinase B as well as the small GTPases Rac and Cdc42. In turn Rac mediates p38 mitogen-activated protein (MAP) kinase activation and cytoskeletal reorganization, whereas factor VIIa-induced p42/p44 MAP kinase stimulation required PI3K enzymatic activity but was not inhibited by dominant negative Rac proteins. We propose that this Src family member/PI3K/Rac-dependent signaling pathway is a major mediator of factor VIIa/TF effects in pathophysiology.
...
PMID:Factor VIIa/tissue factor-induced signaling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac. 1084 1
1
2
3
4
5
6
7
8
9
10
Next >>